Bristol Myers Squibb released a significant announcement on Wednesday that it is collaborating with Anthropic to make its Claude AI model available to over 30,000 employees.

The primary motive behind this partnership is to accelerate the discovery, development and delivery of new medicines. Bristol said it is also working to influence Claude Code, Anthropic’s coding tool, and determine its use in research, drug development, and other commercial affairs.

Meanwhile, drugmakers have been involved in revealing a plethora of deals to realize the potential of artificial intelligence. 

Notably, pharmaceutical giant Eli Lilly has partnered with prominent chipmaker Nvidia to improve the success rate of new drugs in the market.

In this connection, Greg Mayors, chief digital and technology officer said: “Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos, and this collaboration is how we reach it.”

Furthermore, consultancy MC Kinsey said last year that agentic AI which seeks human intervention could increase clinical development productivity by about 35% to 45% over the next five years. 

It is pertinent to note that the model’s performance in cybersecurity is described as far surpassing all existing AI models, marking a major technical milestone for the industry.